National Research Corporation Retained Earnings 2011-2026 | NRC

Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.

Possible uses include

reinvestment in development (R&D, equipment, marketing)
debt repayment
acquisition of other companies
creation of reserves for the future

A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.

The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.

Annual Retained Earnings National Research Corporation

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-30.5 M	-25.2 M	-36.1 M	-61.4 M	-93.4 M	-106 M	77.6 M	71.5 M	65.3 M	73.7 M	58 M	44.7 M	47 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
77.6 M	-106 M	6.53 M

Quarterly Retained Earnings National Research Corporation

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-15.5 M	-16.9 M	-14 M	-17.1 M	-20.9 M	-23.7 M	-	-30.5 M	-36.5 M	-16.8 M	-21.2 M	-25.2 M	-28.9 M	-	-33.6 M	-36.1 M	-42.7 M	-49.3 M	-52.1 M	-61.4 M	-61.4 M	-61.4 M	-61.4 M	-93.4 M	-93.4 M	-93.4 M	-93.4 M	-106 M	-106 M	-106 M	-106 M	77.6 M	77.6 M	77.6 M	77.6 M	71.5 M	71.5 M	71.5 M	71.5 M	65.3 M	65.3 M	65.3 M	65.3 M	73.7 M	73.7 M	73.7 M	73.7 M	58 M	58 M	58 M	58 M	44.7 M	44.7 M	51.3 M	44.7 M	47 M	47 M	47 M	47 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
77.6 M	-106 M	4.08 M

Retained Earnings of other stocks in the Diagnostics research industry

Issuer	Retained Earnings	Price	% 24h	Market Cap	Country
Centogene N.V. CNTG	-62.9 M	-	-6.23 %	$ 30.6 M	Germany
Akumin AKU	-280 M	-	-17.87 %	$ 25.9 M	Canada
Aspira Women's Health AWH	-499 M	-	-6.19 %	$ 10.5 M	USA
Burning Rock Biotech Limited BNR	-2.23 B	$ 33.55	-1.5 %	$ 377 M	China
Brainsway Ltd. BWAY	-77.3 M	$ 23.55	0.73 %	$ 99.4 M	Israel
Biocept BIOC	-298 M	-	-13.05 %	$ 7.29 M	USA
Accelerate Diagnostics AXDX	-607 M	-	-61.36 %	$ 2.46 M	USA
BioNano Genomics BNGO	-693 M	$ 1.27	-1.92 %	$ 1.61 M	USA
Check-Cap Ltd. CHEK	-170 M	-	-	$ 9.42 M	Israel
Oxford Immunotec Global PLC OXFD	-84 M	-	-	$ 562 M	Britain
Chembio Diagnostics CEMI	-154 M	-	0.22 %	$ 16.8 M	USA
Castle Biosciences CSTL	-200 M	$ 40.56	2.97 %	$ 1.13 B	USA
Co-Diagnostics CODX	4.6 M	-	-	$ 79.8 M	USA
Danaher Corporation DHR	44.2 B	$ 218.21	-0.31 %	$ 160 B	USA
DermTech DMTK	-424 M	-	-11.32 %	$ 2.94 M	USA
Global Cord Blood Corporation CO	2.89 B	-	-	$ 399 M	China
Fluidigm Corporation FLDM	-624 M	-	1.08 %	$ 308 M	USA
Exact Sciences Corporation EXAS	-4.5 B	$ 102.48	0.14 %	$ 19 B	USA
Genetic Technologies Limited GENE	-150 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	-4.94 B	-	0.12 %	$ 80.1 M	China
PRA Health Sciences, Inc. PRAH	440 M	-	-	$ 10.7 B	USA
DexCom DXCM	1.02 B	$ 73.22	0.25 %	$ 28.3 B	USA
CareDx, Inc CDNA	-678 M	$ 21.0	2.19 %	$ 1.13 B	USA
Celcuity CELC	-272 M	$ 111.37	1.78 %	$ 4.39 B	USA
Guardant Health GH	-2.58 B	$ 114.82	0.68 %	$ 14.1 B	USA
DarioHealth Corp. DRIO	-349 M	$ 10.2	1.8 %	$ 289 M	Israel
Enzo Biochem ENZ	-294 M	-	-8.98 %	$ 14.8 K	USA
Fulgent Genetics FLGT	590 M	$ 26.24	0.15 %	$ 793 M	USA
HTG Molecular Diagnostics HTGM	-230 M	-	-20.0 %	$ 1.06 M	USA
Heska Corporation HSKA	-169 M	-	-	$ 1.31 B	USA
IDEXX Laboratories IDXX	5.33 B	$ 643.58	-4.01 %	$ 53.1 B	USA
Illumina ILMN	-1.24 B	$ 142.0	-1.94 %	$ 22.6 B	USA
QIAGEN N.V. QGEN	2.45 B	-	-	$ 10.6 B	Niderland
Lantheus Holdings LNTH	446 M	$ 67.41	0.73 %	$ 4.66 B	USA
IQVIA Holdings IQV	6.06 B	$ 229.9	-0.11 %	$ 41.7 B	USA
Medpace Holdings MEDP	8.17 M	$ 589.59	1.22 %	$ 18.3 B	USA
Charles River Laboratories International CRL	1.81 B	$ 210.66	0.04 %	$ 10.8 B	USA
NeoGenomics NEO	-326 M	$ 12.17	0.79 %	$ 1.54 B	USA
Quest Diagnostics Incorporated DGX	9.36 B	$ 183.26	-1.98 %	$ 20.3 B	USA
Biodesix BDSX	-462 M	$ 9.32	-8.36 %	$ 1.21 B	USA
Precipio PRPO	-98.2 M	$ 24.54	0.04 %	$ 31.8 M	USA
Laboratory Corporation of America Holdings LH	8.3 B	$ 266.32	-1.91 %	$ 22.3 B	USA
Personalis PSNL	-550 M	$ 9.43	0.59 %	$ 559 M	USA
ICON Public Limited Company ICLR	2.72 B	$ 180.05	-0.11 %	$ 14.9 B	Irlanda
Agilent Technologies A	348 M	$ 133.97	0.07 %	$ 40.7 B	USA
Biomerica BMRA	-53.2 M	$ 2.38	-	$ 5.47 M	USA
OpGen OPGN	-294 M	-	-16.95 %	$ 1.54 M	USA
Bioventus BVS	-322 M	$ 8.16	2.9 %	$ 511 M	USA